Impact of Blastocyst Morphological Development and Blastocoele Re-expansion on Pregnancy Outcome After Using REKOVELLE®

TerminatedOBSERVATIONAL
Enrollment

362

Participants

Timeline

Start Date

September 1, 2018

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
Controlled Ovarian Stimulation
Interventions
DRUG

Follitropin Delta

"The Intervention (solution for injection) is delivered with an injection pen. For women with AMH \<15 pmol/L the daily dose is 12 micrograms, irrespective of body weight. For women with AMH ≥15 pmol/L the daily dose decreases from 0.19 to 0.10 micrograms/kg by increasing AMH concentration. The maximum daily dose for the first treatment cycle is 12 micrograms.~For subsequent treatment cycles, the daily dose of REKOVELLE® should be maintained or modified according to the patient's ovarian response in the previous cycle. Based on the ovarian hypo/hyper-response in the previous cycle, the daily dose in the subsequent cycle should be increased (by 25% or 50%) or decreased (by 20% or 33%). The maximum daily dose is 24 micrograms."

Trial Locations (1)

Unknown

Ciconia, VivaNeo (there may be other sites in this country), Højbjerg

Sponsors
All Listed Sponsors
lead

Ferring Pharmaceuticals

INDUSTRY